Currently out of the existing stock ratings of Steven Lichtman, 143 are a BUY (89.94%), 16 are a HOLD (10.06%).

Steven Lichtman

Work Performance Price Targets & Ratings Chart

Analyst Steven Lichtman, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 66.07% that have a potential upside of 31.46% achieved within 269 days.

Steven Lichtman’s has documented 339 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PODD, Insulet at 20-May-2026.

Wall Street Analyst Steven Lichtman

Analyst best performing recommendations are on CFMS (CONFORMIS).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 2/27/2019. The price target of $68 was fulfilled within 2 days with a profit of $6.14 (9.93%) receiving and performance score of 49.63.

Average potential price target upside

of $22.88 (20.51%) on ZBH (ZIMMER BIOMET HOLDINGS).
of $21.81 (32.56%) on GKOS (GLAUKOS CORP).
of $21.43 (34.49%) on MDT (MEDTRONIC PLC).

BSX Boston Scientific Corp DXCM DexCom ELGX Endologix GKOS Glaukos Corp GMED Globus Medical IART Integra LifeSciences Holdings MDT Medtronic PLC ORGO Organogenesis Holdings PODD Insulet SYK Stryker TNDM Tandem Diabetes Care ZBH Zimmer Biomet Holdings ALC Alcon AG CFMS ConforMIS COO The Cooper Companies Common Stock MMSI Merit Medical Systems MNKD MannKind Corp BWAY Brainsway Ltd RXST Rxsight MODD Modular Medical NSPR InspireMD RWLK Rewalk Robotics Ltd WMGI Wright Medical Group N.V

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

John Eade (ARGUS)